rk, last year with this annual reporting they also diluted on 8/30/2013. It's my main concern. Wish I knew the answer. I don't know whether to expect a pop or drop.
I haven't reloaded yet. Still sucking wind on MNKD. I'm not a technician, but moodwise unless there is a catalyst I don't see why it couldn't go into prior range where one could reload in the high 1.60s low 1.70s again. The rise was pretty much on no news. Then we received finally an update on the AD trial, and it helped, but did not resurrect likelihood of PBT2 obtaining accelerated approval for AD, and lacking cognitive improvement - reduced atrophy might be a path, but only if accepted someday as a surrogate measure and I don't hear any talk of that coming from the FDA at this point in time.
I still think there are potential catalysts that would take us much, much higher. Such a catalyst could come at any time. It's just whether something like that will come along at the right time is a crapshoot.
My hopes for the open label extension to possibly resurrect hope for PBT2s accelerated approval for AD, in addition to additional progress toward PBT2 for HD. HD is a rare disease. One possibility is that if PBT2 is only approved for HD, the pricing could be substantially higher in accordance with industry practice.
Glad to see Finkelstein's as having work paid for by Prana.
When previously upon issue of new significant patents a news release comes out next day, but this time silence it adds to the notion they are in a quiet period. However, it could be entirely earnings related at this point in time.
So the only other explanation if a news release doesn't come out is that they are in a quiet period due to partnership or buyout announcement.....
Let's see...insiders taken care of....loaded up
Debtor Deerfield taken care of....in for max pain & gain when shorts said he didn't have another 40Mill
I believe that means shareholder's next....I'm ready
Bring it on
In this example it took a day:
MannKind Corporation Announces Issuance of Two Key U.S. Patents
VALENCIA, Calif., Feb. 8 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Patent and Trademark Office has awarded the company two key patents relating to a method for inducing a cytotoxic T cell (CTL) response that will be utilized with the company's cancer immunotherapy products. MannKind is in late stage preclinical testing of therapeutic vaccines for treatment of colorectal, renal, ovarian, pancreatic and breast cancers. The company believes these vaccines will likely improve outcomes for a substantial portion of patients suffering from these cancers.
U.S. Patent 6,994,851, issued yesterday, claims methods of obtaining a sustained CTL response by delivery of antigen to the lymphatic system, particularly intranodally, and maintaining the antigen in the lymphatic system over time. The method allows for the prolongation of the effector phase of the CTL response and can be applied to the treatment of cancer and chronic infections.
U.S. Patent 6,977,074, issued December 20, 2005, claims methods of inducing a CTL response by delivering antigen directly to a lymph node or lymph vessel. Direct intralymphatic administration enables more efficient induction of CTL responses than can generally be obtained using more conventional routes of administration with any amount of antigen. This can be particularly advantageous when using DNA vaccines or small peptides to provide antigen.
David Diamond, Director of Intellectual Property for MannKind Corporation, commented, "The issuance of these patents provides a strong proprietary foundation for our cancer immunotherapy program. Intralymphatic delivery greatly increases the number of CTL's against the cancer cells, wherever they may be in the body. In this way the body's natural immune system destroys the cancer without harm to normal cells and should improve efficacy and safety without ...
Nice the we cater to the preppers in this day and age. Sweet! It may soon comprise most of the population. Definitely a blockbuster drug...
What we have is proof that those shorts that were spouting that Deerfield did not have another 40 Million to loan were proven wrong, and the strength of MNKDs negotiation position just got $40 Million stronger.
I agree the comments were like hit pieces where they can't appreciate having a new tool at their disposal to use to fight diabetes, and the one was like...and when I grew up our needles were six inches long, we had to first stick them in a fire to sterilize them AND WE LIKED IT! Give us a break! Let's have an alternative to shots where they can be found, even if only to reduce frequency.
I know, I know. i loaded up big at 1.70 and sold periodically on the way up beginning around 2.10, and just got to selling too much between 2.20 & 2.30, so now sort of passing up gains.
Percentage wise I need to cut down and take less off the table when selling into a rise and be sure to always keep a core amount. I can at least say I am passing up gains after taking a nice profit.
I just didn't feel the first part of this run was driven by volume, and only now that we are significantly up from those recent 1.70s lows do you see the volume, and constantly more volume on the ask - folks are taking profits here basically it appears to me.
Part of my decision was that I sold quite a bit to buy the dip late in the day just after MNKD FDA approval. That's turning out to require some patience. I'm hoping a little patience will pay off there as well, but I'm stuck with quite a bit there as I wait.
I don't have level 2 these days, but there is constantly more showing on the sell than the by every time I look during this runup. It's been a relatively low volume runup with hardly any options volume to suggest anything is imminent. I have traded out of some shares and a bit scared to buy in, even though I might miss a run.
Just thoughts from anyone on the chart.
Being a finance guy, I don't buy the arguments that we could not see dilution in any form such as a new ATM, etc.
That being said, there are certainly catalysts that if announced and good could double this stock in a heartbeat. I would be more scared to short this then buy it. Mostly watching for now.
Can any chartists tell me what lies ahead?
P.S. I already know Goutah's opinion on chartists and technical trading, in general.
I absolutely think HD must move forward as currently our only fast-track to market. If the open label extension revives the potential for acceleration to market for AD, then that also should proceed. If it doesn't Pran will need to consider these tough questions. If we are going back to squares with a new larger trial what provides the best chance for success and the largest market would be two good questions to ponder.
With the safety profile so far demonstrated of PBT2, and the results of the Normal Aged Mice study now to consider, would shelving PBT2 for solely AD, and going for the limitless market of Normal Age-related Cognitive Decline be an approach that might actually provide a shareprice catalyst, due to the fact that the entire AD market could be included in off-label use if approved for normal age-related cognitive decline.
Just to be complete, there is an Oxford study titled Preventing Alzheimer's disease-related grey matter atrophy by B-vitamin treatment.
High-dose B-vitamin treatment (folic acid 0.8 mg, vitamin B6 20 Mg, vitamin B12 -.5 mg) treatment reduces, by as much as seven fold, the cerebral atrophy in those gray matter (GM) regions specifically vulnerable to the AD process, including the medial temporal lobe. However, this benefit was confined to participants with high homocysteine (above the median), and that, in these participants, a causal Bayesion network analysis indicated the follwoign chain of events: B vitamins lower homocysteine, which directly leads to a decrease in GM atrophy.
The study was conducted over 2 years.
That being said, since this is a natural remedy few will pay any attention to it, but I have been incorporating this regimine since the study was brought to the board (possibly by you, inverser86?). Thanks for all your contributions. I believe there are also other B-vitamin studies in differing dosages that did not yield these results.
I will say anectodally, that the regimine seems to wake up my mind about the same as a cup of coffee - it seems to kick start the brain. Before doing it, I needed my coffee to get going. When taking it - I could probably stop drinking coffee without feeling like I'm slow to get going in the morning. I do take it first thing in the morning.
OMER is a nice recent example that received FDA approval on June 2nd and actually dipped afterwards for 2 days into low 11s and has since steadily marched up to $18 per share. Hopefully pain will be over soon.
I was in MNKD for most of the run towards approval, exited ahead of the binary event and then bought the news Friday after hours and have no regrets about it.
I also bought OMER on June 5 & June 6 after it bottomed - buying in at 11.22 and 11.75. I recently sold in the 16s & 17s and that is beginning to look like a mistake on my part.